← Back to Search

Anti-tumor antibiotic

Relacorilant, 150mg QD for Fallopian Tube Cancer

Phase 2

Waitlist Available

Research Sponsored by Corcept Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months from enrollment of last subject

Awards & highlights

Study Summary

This trial is testing whether adding the drug relacorilant to the standard treatment for ovarian cancer (nab-paclitaxel) improves progression-free survival. Patients will be randomly assigned to one of three treatment groups: relacorilant plus nab-paclitaxel given intermittently, relacorilant plus nab-paclitaxel given continuously, or nab-paclitaxel given alone.

Eligible Conditions

Fallopian Tube Cancer
Peritoneal Carcinoma
Ovarian Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months from enrollment of last subject

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months from enrollment of last subject

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months from enrollment of last subject for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Progression Free Survival (PFS)

Secondary outcome measures

Best Overall Response (BoR)

Best Overall Response in patients who crossover to continuous treatment at time of PD

Cancer Antigen (CA)-125 Response

+9 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Intermittent Relacorilant DosingExperimental Treatment2 Interventions

Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

Group II: Continuous Relacorilant DosingExperimental Treatment2 Interventions

Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

Group III: Nab-paclitaxel ComparatorActive Control1 Intervention

Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Corcept TherapeuticsLead Sponsor

68 Previous Clinical Trials

6,202 Total Patients Enrolled

Dorothy Nguyen, MDStudy DirectorCorcept Therapeutics

5 Previous Clinical Trials

423 Total Patients Enrolled

Lyndah Dreiling, MDStudy DirectorCorcept Therapeutics

5 Previous Clinical Trials

755 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many locales are being utilized for this research endeavor?

"Patients are being recruited from the following sites: Site Reference ID/Investigator #032 in Denver, Colorado; Site Reference ID/Investigator #135 in Charlottesville, Virginia; and Site Reference ID/Investigator#001 in Chicago, Illinois. Additionally, 11 more clinical trial locations exist throughout the country."

Answered by AI

Has Relacorilant 100mg QD been tested in any previous clinical experiments?

"Relacorilant, 100mg QD was initially trialled in 1997 at the City of Hope Comprehensive Cancer Center and has since seen 1153 studies to completion. Of these trials, 834 are currently active with a considerable amount hosted by Denver's medical facilities."

Answered by AI

Has the FDA sanctioned Relacorilant, 100mg QD for consumption?

"Our professionals at Power gave the safety of Relacorilant, 100mg QD a score of 2. This is due to its Phase 2 trial status; which indicates that there are only some data points supporting its safety but no evidence for efficacy yet."

Answered by AI

Does this clinical investigation have any vacancies for participants?

"According to the clinicaltrials.gov website, this medical trial is no longer accepting applicants for its study. Originally posted on January 28th 2019 and last updated June 27th 2022, unfortunately there are not any vacant positions available in this particular experiment; however 4463 other trials remain open for recruitment at present."

Answered by AI

What medical issue is Relacorilant, 100mg QD typically utilized to treat?

"Relacorilant, 100mg QD is the prescribed treatment for neoplasm metastasis and has demonstrated efficacy against Kaposi sarcoma, advanced directives, and fallopian tube cancer."

Answered by AI

What is the current enrollment cap for this clinical experiment?

"Patient recruitment for this trial has been terminated. Initially posted on January 28th, 2019 and last updated June 27th, 2022, the study is no longer enrolling participants. However there are other medical trials open for enrollment; with 3629 studies actively admitting patients suffering from relapse and 834 trails recruiting folks taking Relacorilant 100mg QD daily."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

2019. "Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03776812.

All > Peritoneal Cancer